In light of the increased clinical efforts to use SAHA and other HDAC inhibitors for breast cancer therapy, our data suggest that both the BRCA1 status and the hypoxic tumor microenvironment are potential important parameters that may affect the clinical efficacy of HDAC inhibitors. Here, BRCA1 is linked to breast cancer.